Table 1. EBV gene expression in breast cancer and controls.
Breast samples |
|||||||||
EBV genes | BC 1 | BC 4 | BC 10 | BC 11 | BC 12 | BC 13 | 9 | 14 | C 15 |
BZLF1 | − | − | − | − | + | − | − | − | + |
CST (BART) | + | + | + | + | + | + | + | + | + |
IR4/LF3 (Raji seq) | + | + | + | + | + | + | − | − | − |
IR4/LF3 (C15 seq) | + | – | + | + | + | + | − | − | + |
EBNA1 (Qp) | − | − | + | + | − | + | − | − | + |
EBER2 | − | − | − | − | − | − | + | − | + |
Negative in breast cancers: EBER1, EBNA1 (Cp/Wp), BHRF1, IR2/BHLF1, LMP1, LMP2A. BC 1=NHS BSP grade II ductal carcinoma; BC 4=mixed pattern carcinoma, ductal elements present; BC 10=high-grade ductal carcinoma; BC 11=ductal carcinoma; BC 12=NHS BSP grade II infiltrating ductal carcinoma; BC 13=NHS BSP grade III invasive ductal carcinoma; 9=cervical lymph node; 14=HD; C15=NPC xenograft (Busson et al, 1988).